

**Paolo G. Casali**

**Last DOI update: May 19, 2022**

### Financial Interests

Advenchen, Funding, Institutional, Financial interest  
Amgen Dompé, Funding, Institutional, Financial interest  
AROG Pharmaceuticals, Funding, Institutional, Financial interest  
Bayer, Funding, Institutional, Financial interest  
Blueprint, Funding, Institutional, Financial interest  
Daiichi, Funding, Institutional, Financial interest  
Deciphera, Funding, Institutional, Financial interest  
EISAI, Funding, Institutional, Financial interest  
Eli Lilly, Funding, Institutional, Financial interest  
Epizyme, Funding, Institutional, Financial interest  
GlaxoSmithKlein, Funding, Institutional, Financial interest  
Karyopharm, Funding, Institutional, Financial interest  
Novartis, Funding, Institutional, Financial interest  
Pfizer, Funding, Institutional, Financial interest  
PharmaMar, Funding, Institutional, Financial interest

### Non-Financial Interests

Rare Cancers Europe, Leadership Role, Coordinator of the Steering Committee



**Annalisa Trama**

**Last DOI update: April 3, 2022**

**I confirm that I have no interests to declare**